CYMAT ANNOUNCES TSX-V APPROVAL OF $1.3 M PRIVATE PLACEMENT FINANCING
Cymat Technologies (TSXV: CYM) (OTCQB: CYMHF) has received TSX Venture Exchange approval for a non-brokered private placement, raising $1,283,858 in gross proceeds. The offering consists of Units priced at $0.11, with each Unit comprising one Common Share and one Common Share Purchase Warrant.
The company will issue 11,671,435 Common Shares and an equal number of Warrants. Each Warrant allows holders to purchase one Common Share at $0.13 within 24 months, subject to acceleration if share prices remain at or above $0.16 for 10 consecutive trading days. A company insider participated with a $100,000 subscription.
The proceeds will fund capital equipment purchases for a strategic business development initiative and working capital requirements. Securities issued will have a trading hold period expiring August 16, 2025.
Cymat Technologies (TSXV: CYM) (OTCQB: CYMHF) ha ottenuto l'approvazione dalla TSX Venture Exchange per un collocamento privato senza intermediari, raccogliendo 1.283.858 $ di proventi lordi. L'offerta comprende Unit a un prezzo di 0,11 $, ciascuna composta da un'Azione Ordinaria e da un Warrant per l'acquisto di un'Azione Ordinaria.
La società emetterà 11.671.435 Azioni Ordinarie e un pari numero di Warrant. Ogni Warrant consente ai titolari di acquistare un'Azione Ordinaria a 0,13 $ entro 24 mesi, con possibilità di accelerazione se il prezzo delle azioni rimane a o sopra 0,16 $ per 10 giorni di negoziazione consecutivi. Un soggetto interno all'azienda ha partecipato con una sottoscrizione di 100.000 $.
I proventi saranno destinati all'acquisto di attrezzature capitali per un'iniziativa strategica di sviluppo aziendale e per esigenze di capitale circolante. I titoli emessi saranno soggetti a un periodo di blocco fino al 16 agosto 2025.
Cymat Technologies (TSXV: CYM) (OTCQB: CYMHF) ha recibido la aprobación de la TSX Venture Exchange para una colocación privada sin intermediarios, recaudando 1.283.858 $ en ingresos brutos. La oferta consiste en Unidades con un precio de 0,11 $, cada una compuesta por una Acción Común y un Warrant para la compra de una Acción Común.
La compañía emitirá 11.671.435 Acciones Comunes y un número igual de Warrants. Cada Warrant permite a los tenedores comprar una Acción Común a 0,13 $ dentro de 24 meses, con posibilidad de aceleración si el precio de las acciones se mantiene en o por encima de 0,16 $ durante 10 días hábiles consecutivos. Un insider de la empresa participó con una suscripción de 100.000 $.
Los fondos se destinarán a la compra de equipos de capital para una iniciativa estratégica de desarrollo empresarial y necesidades de capital de trabajo. Los valores emitidos tendrán un período de retención hasta el 16 de agosto de 2025.
Cymat Technologies (TSXV: CYM) (OTCQB: CYMHF)가 TSX 벤처 거래소로부터 중개인 없이 진행하는 사모 발행 승인을 받아 총 1,283,858 달러의 총 수익을 조달했습니다. 이번 공모는 단가 0.11달러인 유닛(Unit)으로 구성되며, 각 유닛은 보통주 1주와 보통주 매수 워런트 1주로 이루어져 있습니다.
회사는 11,671,435주의 보통주와 동일 수량의 워런트를 발행할 예정입니다. 각 워런트는 보유자가 24개월 이내에 0.13달러에 보통주 1주를 매수할 수 있는 권리를 부여하며, 주가가 연속 10거래일 동안 0.16달러 이상일 경우 조기 행사 조건이 적용됩니다. 회사 내부자도 100,000 달러 상당을 청약에 참여했습니다.
조달된 자금은 전략적 사업 개발 이니셔티브를 위한 자본 장비 구매와 운전자본 요구에 사용될 예정입니다. 발행된 증권은 2025년 8월 16일까지 거래 제한 기간이 적용됩니다.
Cymat Technologies (TSXV : CYM) (OTCQB : CYMHF) a obtenu l'approbation de la TSX Venture Exchange pour un placement privé sans courtier, levant 1 283 858 $ de produits bruts. L'offre consiste en des unités au prix de 0,11 $, chaque unité comprenant une action ordinaire et un bon de souscription d'action ordinaire.
La société émettra 11 671 435 actions ordinaires et un nombre égal de bons de souscription. Chaque bon permet à son détenteur d'acheter une action ordinaire à 0,13 $ dans les 24 mois, avec une possibilité d'accélération si le cours de l'action reste à 0,16 $ ou plus pendant 10 jours de bourse consécutifs. Un initié de la société a participé avec une souscription de 100 000 $.
Les fonds serviront à financer des achats d'équipements d'investissement dans le cadre d'une initiative stratégique de développement commercial ainsi que les besoins en fonds de roulement. Les titres émis seront soumis à une période de blocage jusqu'au 16 août 2025.
Cymat Technologies (TSXV: CYM) (OTCQB: CYMHF) hat die Genehmigung der TSX Venture Exchange für eine nicht vermittelte Privatplatzierung erhalten und dabei 1.283.858 $ Bruttoerlös erzielt. Das Angebot besteht aus Einheiten zum Preis von 0,11 $, wobei jede Einheit aus einer Stammaktie und einem Warrant zum Kauf einer Stammaktie besteht.
Das Unternehmen wird 11.671.435 Stammaktien und eine gleiche Anzahl von Warrants ausgeben. Jeder Warrant berechtigt die Inhaber, innerhalb von 24 Monaten eine Stammaktie zu 0,13 $ zu kaufen, mit der Möglichkeit zur Beschleunigung, falls der Aktienkurs an 10 aufeinanderfolgenden Handelstagen bei oder über 0,16 $ bleibt. Ein Unternehmensinsider hat sich mit einer Zeichnung von 100.000 $ beteiligt.
Die Erlöse werden für den Kauf von Investitionsgütern im Rahmen einer strategischen Geschäftsentwicklungsinitiative und für den Betriebskapitalbedarf verwendet. Die ausgegebenen Wertpapiere unterliegen einer Haltefrist bis zum 16. August 2025.
- Secured $1.28M in additional funding through private placement
- Insider participation of $100,000 demonstrates management confidence
- Minimal finder's fees of $4,191 indicates efficient capital raising
- Proceeds earmarked for strategic business development initiative
- Dilutive effect from issuing 11.67M new shares and warrants
- Low unit pricing at $0.11 indicates weak market valuation
- Additional dilution possible if warrants are exercised
Each Unit was priced at
As the result of this Offering, Cymat will issue 11,671,435 Common Shares and the same number of Common Share Purchase Warrants. Aggregate finder's fees of
A Cymat insider subscribed for 909,090 Units reflecting gross proceeds of
Proceeds of the Offering will be used for capital equipment purchases in support of a major strategic business development initiative and for working capital requirements.
In accordance with applicable Canadian securities laws, the securities issued under this Offering will be subject to a trading hold period that will expire on August 16, 2025.
About Cymat Technologies Ltd.
Cymat Technologies Ltd. has the global rights, through patents and established know-how, to manufacture and sell Stabilized Aluminum Foam ("SAF"), a unique, ultra-light, cellular metallic material. The proprietary production process entails the injection of gases through a molten bath of alloyed aluminum infused with ceramic particles. The result is an advanced, lightweight, recyclable material that exhibits unique characteristics including customizable density and dimensions; mechanical energy absorption; thermal and acoustic insulation; and time, temperature and strain-rate insensitivity. A key benefit of this continuous foam production process is its scalability and resultant low cost of production. SAF is used in such industries as architectural design, military and automotive. Cymat markets its architectural SAF under the AlusionTM brand and its automotive and military SAF under the SmartMetalTM brand. For further information, please visit our website at www.cymat.com.
Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions and dependence upon regulatory approvals. Certain material assumptions regarding such forward-looking statements may be discussed in this news release and the Company's annual and quarterly management's discussion and analysis filed at www.sedar.com. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cymat-announces-tsx-v-approval-of-1-3-m-private-placement-financing-302429496.html
SOURCE Cymat Technologies Ltd.
FAQ
What are the terms of Cymat Technologies' (CYMHF) private placement financing?
How much did Cymat Technologies (CYMHF) raise in their April 2025 private placement?
What is the lock-up period for CYMHF's private placement securities?
How will Cymat Technologies (CYMHF) use the private placement proceeds?
What is the warrant acceleration clause in CYMHF's private placement?
